about
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistTranscriptome sequencing to detect gene fusions in cancerMetabolomic profiles delineate potential role for sarcosine in prostate cancer progressionIdentification of targetable FGFR gene fusions in diverse cancers.Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Expressed pseudogenes in the transcriptional landscape of human cancersGene Fusion Markup Language: a prototype for exchanging gene fusion dataIntegrative molecular concept modeling of prostate cancer progression.Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.HPeak: an HMM-based algorithm for defining read-enriched regions in ChIP-Seq data.Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer.Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanomaPersonalized oncology through integrative high-throughput sequencing: a pilot study.miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancersTranscriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinomaFunctionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.Molecular concepts analysis links tumors, pathways, mechanisms, and drugsHeat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C DiseaseGene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancerLandscape of gene fusions in epithelial cancers: seq and ye shall find.Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing.Outlier kinase expression by RNA sequencing as targets for precision therapy.Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer.Chimeric transcript discovery by paired-end transcriptome sequencingInflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer.Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencingMining for regulatory programs in the cancer transcriptome.Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database.Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes.Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.Humoral response profiling reveals pathways to prostate cancer progression.A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis?Erratum: Corrigendum: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionProbabilistic model of the human protein-protein interaction network
P50
Q24652842-3DF4AA83-9CA7-4189-A550-39E453EE4169Q24653386-F9272928-838C-4497-BC0F-E47D3B455BF1Q24654019-5D732BDF-60C7-4B4A-B5FE-4A74CD1424A9Q27852147-A7B58CF9-4A38-4263-A391-74D00DE07CA6Q27852630-443B667B-1355-4023-83D3-A4982F1EA790Q28703606-C39EC299-4295-456F-B6B1-6968BC9826F9Q30573694-C3AB5AC2-A3FB-4A27-8274-2746B709BBE6Q33266777-A9F79FB0-F870-47A9-960F-F98EA40DA51CQ33405269-E0B58EB9-7E9E-4CEE-B327-13EE8B009CB0Q33624191-E31497B6-E398-4BFB-9DAA-78BFBA5C3D96Q33697764-264B4C72-EF0A-40A7-8C95-179262ACD6B8Q33949373-B976F7D9-1818-4A54-A613-A799A5ADE07FQ33992803-1BB2EBAA-EA2D-469F-ABBE-F3CB150EFAC2Q34237470-377DD66A-038F-4D82-A4C0-DC4264564BBBQ34623368-496CF627-23BC-408A-85FE-6A2F8F506F10Q34762165-3E757BF9-7D95-427C-9A2A-8CDB7FF4CFECQ35159486-DE0587D5-BBB1-4FDB-9998-1BDB71083E31Q35600870-91A7AA3A-3864-4563-A404-88D1BF1C9885Q35812701-180AD80B-08D5-4850-B3BB-946E8E3DD3ABQ36010596-A4DF5647-A9D6-4302-B191-0A36ED9818C2Q36200413-A3F9A3BD-6D0E-496C-A089-C82C877EE61BQ36383369-2DC09873-96E9-4164-B7B2-C7627917588AQ36637610-6B2D794D-D504-4A47-B97E-A497FE6475C9Q36684356-DE294D61-E5B9-4FFB-9C22-EDD4348B2B24Q36684371-EF091028-61CD-484D-AD15-88E37EA0FFD7Q36998286-1FD116A4-91B3-4F05-870F-D90028245F9FQ37257656-0A8B5450-92C9-433C-9FD9-7C10C41E8E1CQ37489235-E4283AC9-B595-4D00-950B-B498A4B2D042Q37605989-6F826D28-823B-48E0-B68D-6D1CF141616EQ38325769-96FBE43E-BD6B-48F8-B2D8-8EAEF1B0F98EQ38668393-59D1F0F6-9037-4603-ABB6-F7A48147023DQ38822774-94E50FF1-E9BE-4FB0-B4AC-3D8BBED130EAQ42547252-4A077E0F-07F3-4E38-BCC6-FB4B4CFFCB5DQ46852385-312D0C4B-EA62-4B67-A2F4-97599921B75DQ50565053-E0F45D26-8B25-4AC3-A725-C7014819EE0FQ51240372-DC53B9D2-E536-4809-B3E7-4EBA48806E42Q57267866-8BA2B0CC-2ADC-499D-82D8-1C7F3A2EA384Q58482561-438BDF67-1036-45A8-9733-D205FDA0E684
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shanker Kalyana-Sundaram
@ast
Shanker Kalyana-Sundaram
@en
Shanker Kalyana-Sundaram
@es
Shanker Kalyana-Sundaram
@nl
type
label
Shanker Kalyana-Sundaram
@ast
Shanker Kalyana-Sundaram
@en
Shanker Kalyana-Sundaram
@es
Shanker Kalyana-Sundaram
@nl
altLabel
K Shanker
@en
prefLabel
Shanker Kalyana-Sundaram
@ast
Shanker Kalyana-Sundaram
@en
Shanker Kalyana-Sundaram
@es
Shanker Kalyana-Sundaram
@nl
P106
P1153
8663734900
P31
P496
0000-0002-7309-3848